Amylyx Pharmaceuticals
Amylyx is seeking an experienced Vice President, CMC Strategy to lead integrated Chemistry, Manufacturing, and Controls strategy, global execution, and lifecycle management across the company's preclinical, clinical, and commercial portfolio. This leader will advance the pipeline by aligning CMC priorities with development plans, global regulatory requirements, and long-term product strategies. The role involves leading the CMC asset leadership and program management organization while partnering closely with cross-functional teams to ensure successful execution and commercial readiness.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for diseases with high unmet needs, including Post-Bariatric Hypoglycemia (PBH), Wolfram Syndrome, and Amyotrophic Lateral Sclerosis (ALS). Its lead program, Avexitide, is being evaluated in the pivotal Phase 3 LUCIDITY clinical trial for PBH. Amylyx advances its pipeline using rigorous science, well-defined mechanistic rationale, and a strong commitment to the patient communities it serves.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Amylyx Pharmaceuticals.
131% above the average for this role
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating
4 days ago
Director of Regulatory CMC
nuvationbio
Vice President, Head of CMC
Repertoire Immune Medicines
Senior Vice President, Chemistry & CMC
Rezo Therapeutics
Senior Manager, Regulatory Affairs CMC
shionogi
Vice President, Global CMC Regulatory
Revolution Medicines
Vice President, Global CMC Regulatory
Revolution Medicines